Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities
Autore:
Butera, ST;
Indirizzi:
Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Div AIDS STD, Atlanta,GA 30333 USA Ctr Dis Control & Prevent Atlanta GA USA 30333 STD, Atlanta,GA 30333 USA Ctr Dis Control & Prevent, Natl Ctr Infect Dis, TB Lab Res, Atlanta, GA 30333 USA Ctr Dis Control & Prevent Atlanta GA USA 30333 Res, Atlanta, GA 30333 USA
Titolo Testata:
ANTIVIRAL RESEARCH
fascicolo: 3, volume: 48, anno: 2000,
pagine: 143 - 176
SICI:
0166-3542(200012)48:3<143:TTOHIV>2.0.ZU;2-U
Fonte:
ISI
Lingua:
ENG
Soggetto:
TUMOR-NECROSIS-FACTOR; ACTIVE ANTIRETROVIRAL THERAPY; CD4(+) T-CELLS; NF-KAPPA-B; CHRONICALLY INFECTED-CELLS; LONG TERMINAL REPEAT; BLOOD MONONUCLEAR-CELLS; RNA-POLYMERASE-II; PROTEIN-KINASE-C; INTERLEUKIN-1 RECEPTOR ANTAGONIST;
Keywords:
HIV-1 latency; therapeutic intervention; cell models; viral transcription;
Tipo documento:
Review
Natura:
Periodico
Settore Disciplinare:
Life Sciences
Citazioni:
312
Recensione:
Indirizzi per estratti:
Indirizzo: Butera, ST Ctr Dis Control & Prevent, HIV & Retrovirol Branch, Div AIDS STD, Atlanta,GA 30333 USA Ctr Dis Control & Prevent Atlanta GA USA 30333 ta,GA 30333 USA
Citazione:
S.T. Butera, "Therapeutic targeting of human immunodeficiency virus type-1 latency: current clinical realities and future scientific possibilities", ANTIVIR RES, 48(3), 2000, pp. 143-176

Abstract

Factors affecting HIV-1 latency present formidable obstacles for therapeutic intervention. As these obstacles have become a clinical reality, even with the use of potent anti-retroviral regimens, the need for novel therapeutic strategies specifically targeting HIV-1 latency is evident. However, therapeutic targeting of HIV-1 latency requires an understanding of the mechanisms regulating viral quiescence and activation. These mechanisms have beenpartially delineated using chronically infected cell models and, dearly, HIV-I activation from latency involves several key viral and cellular components. Among these distinctive therapeutic targets, cellular factors involved in HIV-1 transcription especially warrant further consideration for rational drug design. Exploring the scientific possibilities of new therapies targeting HIV-1 latency may hold new promise of eventual HIV-1 eradication. (C) 2000 Published by Elsevier Science B.V. All rights reserved.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 22/09/20 alle ore 06:56:24